CD44v9 as a poor prognostic factor of triple-negative breast cancer treated with neoadjuvant chemotherapy

被引:0
作者
Eriko Tokunaga
Aya Fujita
Katsumi Takizawa
Kimiko Baba
Sayuri Akiyoshi
Yoshiaki Nakamura
Hideki Ijichi
Takanobu Masuda
Chinami Koga
Wakako Tajiri
Shinji Ohno
Kenichi Taguchi
Mayumi Ishida
机构
[1] National Hospital Organization Kyushu Cancer Center,Department of Breast Oncology
[2] National Hospital Organization Kyushu Cancer Center,Departments of Pathology
[3] Cancer Institute Hospital,Breast Cancer Center
来源
Breast Cancer | 2019年 / 26卷
关键词
Triple-negative breast cancer; Neoadjuvant chemotherapy; CD44v9; Cancer stemness;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:47 / 57
页数:10
相关论文
共 178 条
[1]  
Cleator S(2007)Triple-negative breast cancer: therapeutic options Lancet Oncol 8 235-244
[2]  
Heller W(2007)The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes Clin Cancer Res 13 2329-2334
[3]  
Coombes RC(2008)Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer J Clin Oncol 26 1275-1281
[4]  
Carey LA(2015)Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer Clin Cancer Res 21 1688-1698
[5]  
Dees EC(2011)Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies J Clin Invest 121 2750-2767
[6]  
Sawyer L(2016)Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection PLoS One 11 e0157368-2442
[7]  
Gatti L(2017)Molecular alterations in triple-negative breast cancer-the road to new treatment strategies Lancet 389 2430-23
[8]  
Moore DT(2011)Deconstructing the molecular portraits of breast cancer Mol Oncol 5 5-728
[9]  
Collichio F(2012)Cancer stem cells: current status and evolving complexities Cell Stem Cell 10 717-197
[10]  
Liedtke C(2016)Current advances in biomarkers for targeted therapy in triple-negative breast cancer Breast Cancer (Dove Med Press) 8 183-930